Focus on HDL: a new treatment paradigm for athero-thrombotic vascular disease

Author： Shah P.K.  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.9, Iss.9, 2000-09, pp. : 2139-2146

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of Platelets in Athero-Thrombotic Events

By  

Current Pharmaceutical Design, Vol. 18, Iss. 33, 2012-11 ,pp. : 5197-5214

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacological Modulation of Microparticle Release: New Strategies for the Management of Atherothrombotic Vascular Disorders

By  

Current Pharmaceutical Design, Vol. 18, Iss. 6, 2012-02 ,pp. : 840-849

Bentham Science Publishers

Access to resources Recommend Favorite

Platelet Turnover in Atherothrombotic Disease

By  

Current Pharmaceutical Design, Vol. 18, Iss. 33, 2012-11 ,pp. : 5328-5343

Bentham Science Publishers

Access to resources Recommend Favorite

Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents

By  

Current Pharmaceutical Design, Vol. 18, Iss. 6, 2012-02 ,pp. : 850-860

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Relevance of Hyperhomocysteinaemia in Atherothrombotic Disease

By Stehouwer C.D.A.  

Drugs & Aging, Vol. 16, Iss. 4, 2000-04 ,pp. : 251-260

Adis International

Access to resources Recommend Favorite